Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances

Biomaterials

Volumn 32, Issue 19, 2011, Pages 4450-4463

  Segal, Ehud ^a   Pan, Huaizhong ^b   Benayoun, Liat ^c   Kopečková, Pavla ^b   Shaked, Yuval ^c   Kopeček, Jindřich ^b   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF UTAH   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Alendronate; HPMA copolymer; Osteosarcoma; Polymer therapeutics; TNP 470

Indexed keywords

ALENDRONATE; HPMA COPOLYMERS; OSTEOSARCOMA; POLYMER THERAPEUTICS; TNP-470;

BONE; CHEMOTHERAPY; COPOLYMERIZATION; COPOLYMERS; ENDOTHELIAL CELLS; FUNCTIONAL POLYMERS; ORGANIC POLYMERS; PLASTIC PRODUCTS; TUMORS;

TOXICITY;

ALENDRONIC ACID; AMINOBISPHOSPHONATE ALENDRONATE; FUMAGILLOL CHLOROACETYLCARBAMATE; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL;

ACRYLAMIDES; ALENDRONATE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CYCLOHEXANES; HUMANS; MALE; MATERIALS TESTING; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; OSTEOSARCOMA; POLYMERS; SESQUITERPENES; TISSUE DISTRIBUTION;

MURINAE;

EID: 79955130099     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.02.059     Document Type: Article

References (79)

1. Kansara M., Thomas D.M. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 2007, 26:1-18.
2. DuBois S., Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007, 109:813-819.
3. Bielack S.S., Marina N., Ferrari S., Helman L.J., Smeland S., Whelan J.S., et al. Osteosarcoma: the same old drugs or more?. J Clin Oncol 2008, 26:3102-3103.
4. Roodman G.D. Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 1993, 53(Suppl. 1):S94-S98.
5. Harvey H.A., Cream L.R. Biology of bone metastases: causes and consequences. Clin Breast Cancer 2007, 7(Suppl. 1):S7-S13.
6. Berenson J.R., Lipton A. Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med 1999, 50:237-248.
7. Lipton A. Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 2008, 34(Suppl. 1):S25-S30.
8. Orcel P., Beaudreuil J. Bisphosphonates in bone diseases other than osteoporosis. Joint Bone Spine 2002, 69:19-27.
9. Hillner B.E. The role of bisphosphonates in metastatic breast cancer. Semin Radiat Oncol 2000, 10:250-253.
10. Koka S., Salinas T.J., Kennel K.A. Osteoporosis, fracture risk, and prosthodontic implications. Int J Prosthodont 2009, 22:505-506.
11. Leah E. Therapy: bisphosphonate users: cancer risk. Nat Rev Rheumatol 2010, 6:616.
12. Kennel K.A., Drake M.T. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009, 84:632-637.
13. Quan G.M., Choong P.F. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev 2006, 25:707-713.
14. Lee Y.H., Tokunaga T., Oshika Y., Suto R., Yanagisawa K., Tomisawa M., et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 1999, 35:1089-1093.
15. Kaya M., Wada T., Nagoya S., Sasaki M., Matsumura T., Yamashita T. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J Bone Joint Surg Br. 2009, 91:784-788.
16. Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
17. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004, 112:496-507.
18. Folkman J. Angiogenesis. Annu Rev Med 2006, 57:1-18.
19. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286.
20. Fernandez P.M., Rickles F.R. Tissue factor and angiogenesis in cancer. Curr Opin Hematol 2002, 9:401-406.
21. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004, 10:255-261.
22. Egerton N. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. Cancer Chemother Pharmacol 2010, 66:1005-1012.
23. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
24. Wong A.L., Chou N., Lee K.M., Ang B.W., Cheng C.L., Lee S.C. Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy. Ann Oncol 2009, 20:1605-1606.
25. Haag R., Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006, 45:1198-1215.
26. Satchi-Fainaro R., Mann-Steinberg H. TNP-470: the resurrection of the first synthetic angiogenesis inhibitor. Angiogenesis: an integrative approach from science to medicine 2008, 387-406. Springer-Verlag, Heidelberg, Germany. W. Figg, J. Folkman (Eds.).
27. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348:555-557.
28. Bhargava P., Marshall J.L., Rizvi N., Dahut W., Yoe J., Figuera M., et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999, 5:1989-1995.
29. Kruger E.A., Figg W.D. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin Investig Drugs 2000, 9:1383-1396.
30. Satchi-Fainaro R., Mamluk R., Wang L., Short S.M., Nagy J.A., Feng D., et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 2005, 7:251-261.
31. Convertine A.J., Ayres N., Scales C.W., Lowe A.B., McCormick C.L. Facile, controlled, room-temperature RAFT polymerization of N-isopropylacrylamide. Biomacromolecules 2004, 5:1177-1180.
32. Segal E., Satchi-Fainaro R. Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deliv Rev 2009, 61:1159-1176.
33. Wang D., Miller S., Sima M., Kopeckova P., Kopecek J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem 2003, 14:853-859.
34. Pan H., Sima M., Kopeckova P., Wu K., Gao S., Liu J., et al. Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharmacol 2008, 5:548-558.
35. Wang D., Miller S.C., Shlyakhtenko L.S., Portillo A.M., Liu X.M., Papangkorn K., et al. Osteotropic peptide that differentiates functional domains of the skeleton. Bioconjug Chem 2007, 18:1375-1378.
36. Husmann K., Muff R., Bolander M.E., Sarkar G., Born W., Fuchs B. Cathepsins and osteosarcoma: expression analysis identifies cathepsin K as an indicator of metastasis. Mol Carcinog 2008, 47:66-73.
37. Pan H., Kopeckova P., Wang D., Yang J., Miller S., Kopecek J. Water-soluble HPMA copolymer-prostaglandin E1 conjugates containing a cathepsin K sensitive spacer. J Drug Target 2006, 14:425-435.
38. Segal E., Pan H., Ofek P., Udagawa T., Kopeckova P., Kopecek J., et al. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 2009, 4:e5233.
39. Talmadge J.E., Singh R.K., Fidler I.J., Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007, 170:793-804.
40. O'Byrne K.J., Dalgleish A.G., Browning M.J., Steward W.P., Harris A.L. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000, 36:151-169.
41. Schein P.S., Scheffler B. Barriers to efficient development of cancer therapeutics. Clin Cancer Res 2006, 12:3243-3248.
42. Giraudo E., Inoue M., Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114:623-633.
43. Khanna C., Prehn J., Yeung C., Caylor J., Tsokos M., Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 2000, 18:261-271.
44. Bertolini F., Mancuso P., Braidotti P., Shaked Y., Kerbel R.S. The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. Biochim Biophys Acta 2009, 1796:27-32.
45. Shaked Y., Bocci G., Munoz R., Man S., Ebos J.M., Hicklin D.J., et al. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets 2005, 5:551-559.
46. Shaked Y., Ciarrocchi A., Franco M., Lee C.R., Man S., Cheung A.M., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313:1785-1787.
47. Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7:101-111.
48. Mancuso P., Colleoni M., Calleri A., Orlando L., Maisonneuve P., Pruneri G., et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006, 108:452-459.
49. Omelyanenko V., Kopeckova P., Gentry C., Kopecek J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release 1998, 53:25-37.
50. Kuljanin J., Jankovic I., Nedeljkovic J., Prstojevic D., Marinkovic V. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions. J Pharm Biomed Anal 2002, 28:1215-1220.
51. Hashimoto K., Morishige K., Sawada K., Tahara M., Kawagishi R., Ikebuchi Y., et al. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res 2005, 65:540-545.
52. Duncan R., Ferruti P., Sgouras D., Tuboku-Metzger A., Ranucci E., Bignotti F. A polymer-Triton X-100 conjugate capable of PH-dependent red blood cell lysis: a model system illustrating the possibility of drug delivery within acidic intracellular compartments. J Drug Target 1994, 2:341-347.
53. Prommer E.E. Toxicity of bisphosphonates. J Palliat Med 2009, 12:1061-1065.
54. Pietschmann P., Stohlawetz P., Brosch S., Steiner G., Smolen J.S., Peterlik M. The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int 1998, 63:325-330.
55. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999, 91:1616-1634.
56. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26:4899-4905.
57. Schneider M., Tjwa M., Carmeliet P. A surrogate marker to monitor angiogenesis at last. Cancer Cell 2005, 7:3-4.
58. Hopewel J.W., Duncan R., Wilding D., Chakrabarti K. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent. Hum Exp Toxicol 2001, 20:461-470.
59. Lee M.J., Veiseh O., Bhattarai N., Sun C., Hansen S.J., Ditzler S., et al. Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. PLoS One 2010, 5:e9536.
60. Inaoka T., Bilbe G., Ishibashi O., Tezuka K., Kumegawa M., Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995, 206:89-96.
61. Kopecek J., Kopeckova P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 2010, 62:122-149.
62. Caraglia M., Santini D., Marra M., Vincenzi B., Tonini G., Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006, 13:7-26.
63. Gittens S.A., Bansal G., Zernicke R.F., Uludag H. Designing proteins for bone targeting. Adv Drug Deliv Rev 2005, 57:1011-1036.
64. Hrubý M., Etrych T., Kučka J., Forsterová M., Ulbrich K. Hydroxybisphosphonate-containing polymeric drug-delivery systems designed for targeting into bone tissue. J Appl Polym Sci 2006, 101:3192-3201.
65. Miller K., Erez R., Segal E., Shabat D., Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl 2009, 48:2949-2954.
66. Abdollahi A., Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010, 13:16-28.
67. Miller S.C., Pan H., Wang D., Bowman B.M., Kopeckova P., Kopecek J. Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats. Pharm Res 2008, 25:2889-2895.
68. Wang D., Miller S.C., Sima M., Parker D., Buswell H., Goodrich K.C., et al. The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study. Pharm Res 2004, 21:1741-1749.
69. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010, 188:759-768.
70. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
71. Iadevaia S., Lu Y., Morales F.C., Mills G.B., Ram P.T. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 2010, 70:6704-6714.
72. Rihova B., Bilej M., Vetvicka V., Ulbrich K., Strohalm J., Kopecek J., et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 1989, 10:335-342.
73. Vasikaran S.D., Khan S., McCloskey E.V., Kanis J.A. Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone 1995, 17:517-520.
74. Weinstain R., Segal E., Satchi-Fainaro R., Shabat D. Real-time monitoring of drug release. Chem Commun (Camb) 2010, 46:553-555.
75. Dass C.R., Choong P.F. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther 2007, 6:3263-3270.
76. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004, 16:143-150.
77. Richmond A., Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Models Mech 2008, 1:78-82.
78. Williams S.S., Alosco T.R., Mayhew E., Lasic D.D., Martin F.J., Bankert R.B. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 1993, 53:3964-3967.
79. Croy B.A., Linder K.E., Yager J.A. Primer for non-immunologists on immune-deficient mice and their applications in research. Comp Med 2001, 51:300-313.